Fig. 1 · Structure

Documents & Downloads

Astragaloside II

Cat. No. A12217 CAS 84676-89-1
Astragaloside II induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Astragaloside II Research Summary

This section summarizes 1 in vitro study and 1 in vivo study of Astragaloside II from 1 published reference. In vitro models include WB-F344 cells.

Astragaloside II In Vitro Studies

Astragaloside II was evaluated in WB-F344 cells using the CCK8 viability assay. Cell viability was not significantly inhibited within 12.5 µM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cell viability in WB-F344 cells

Cell-based study · WB-F344 cells [1]

WB-F344 cells were incubated with Astragaloside II, and viability was assessed using the CCK8 assay. Cell viability was not significantly inhibited within 12.5 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viability is determined by CCK8 assayReported result cell viability is not significantly inhibited within 12.5 µM of these compound[1]

Literature-Reported Treatment Conditions

Treatment concentration
6.25, 12.5, 25, 50 and 100 μM
Exposure duration
for 24 h
Method
the cells are incubated with ASTs and its seven components
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Astragaloside II

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > The inhibitory effects of the main chemical constituents of ASTs on ductular reaction in sodium butyrate-induced WB-F344 cell model (S38, S39, S40, S41); Results > Effects of main chemical constituents of ASTs on SB-induced WB-F344 cell model (S107); FIGURE 5 legend (S136)

Cell viability is determined by CCK8 assay: Cell viability is determined by CCK8 assay; comparator: control group — Results > Effects of main chemical constituents of ASTs on SB-induced WB-F344 cell model (S107); FIGURE 5 legend (S136)

Astragaloside II In Vivo Studies

Astragaloside II was administered to male mice in a CLD model at 50 mg/kg by gavage once daily. Compared with the 0.1% DDC group, CK7 and Col1A1 mRNA expression was significantly reduced in the Astragaloside II group. [1]

Gene Expression in a Mouse CLD Model

Animal study · male C57/BL6J mice; CLD model group; eight mice each [1]

Male mice in a CLD model received Astragaloside II at 50 mg/kg by gavage once daily. Compared with the 0.1% DDC group, CK7 and Col1A1 mRNA expression was significantly reduced in the Astragaloside II group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
gene expressions of CK19, CK7, α-SMA and Col1A1 are evaluated by qRT-PCR, and normalized to GAPDH geneReported result 50 mg/kg astragaloside II group: the mRNA expressions of CK7 and Col1A1 are also significantly reduced in the astragaloside II group (p < 0.01 or p < 0.05)[1]

Conditions shared by the study groups

Route
by gavage
Treatment course
From week five to week 8; once a day
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Astragaloside II 50 mg/kgmodel group are given 0.4% CMC-Na solution by gavage once a day50 mg/kg astragaloside II group: the mRNA expressions of CK7 and Col1A1 are also significantly reduced in the astragaloside II group (p < 0.01 or p < 0.05)[1]
Astragaloside II 50 mg/kg
Model: male C57/BL6J mice; CLD model group; eight mice each
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Astragaloside II

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Animals (S11); Materials and methods > Intervention effects of astragaloside I, astragaloside II, astragaloside IV, cyclogalactol on 0.1 %DDC-induced CLD mouse model (S48, S49, S50, S51); Results > Astragaloside I and cycloastragenol supppressed the expressions of CK19, CK7, α-SMA, COL1A1, IL-1β, and IL-6 in DDC-induced CLD mice (S120); FIGURE 6 legend (S139); FIGURE 7 legend (S145, S148)

gene expressions of CK19, CK7, α-SMA and Col1A1 are evaluated by qRT-PCR, and normalized to GAPDH gene: gene expressions of CK19, CK7, α-SMA and Col1A1 are evaluated by qRT-PCR, and normalized to GAPDH gene; comparator: model group are given 0.4% CMC-Na solution by gavage once a day — Materials and methods > Intervention effects of astragaloside I, astragaloside II, astragaloside IV, cyclogalactol on 0.1 %DDC-induced CLD mouse model (S50); Results > Astragaloside I and cycloastragenol supppressed the expressions of CK19, CK7, α-SMA, COL1A1, IL-1β, and IL-6 in DDC-induced CLD mice (S120); FIGURE 7 legend (S148)

Astragaloside II 50 mg/kg · Materials and methods > Intervention effects of astragaloside I, astragaloside II, astragaloside IV, cyclogalactol on 0.1 %DDC-induced CLD mouse model (S50, S51); Results > Astragaloside I and cycloastragenol supppressed the expressions of CK19, CK7, α-SMA, COL1A1, IL-1β, and IL-6 in DDC-induced CLD mice (S120)

Specifications

Manufacturer Adooq Bioscience
CAS Number 84676-89-1
Formula C43H70O15
Molecular Weight 827.01
Synonyms Astrasieversianin VIII
SMILES
CC(=O)O[C@@H]1[C@H]([C@@H](CO[C@H]1O[C@@]2([C@@H]([C@H](O[C@H]([C@@H]2O)O[C@H]3CC4[C@@]5(C[C@@H]([C@@H]([C@]5(CCC46C[C@]67C3C(CCC7)(C)C)C)[C@]8(CC[C@H](O8)C(C)(C)O)C)O)C)CO)O)O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 86 mg/mL (103.98 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Astragaloside II Research References

  1. [1] Zhang L, Hu Y, Qi S, et al. Astragalus saponins and its main constituents ameliorate ductular reaction and liver fibrosis in a mouse model of DDC-induced cholestatic liver disease. Front Pharmacol (2022). PMID: 36339578 DOI: 10.3389/fphar.2022.965914 Source material

Added to your cart

View Cart Checkout
Loading...